New pill targets tough pancreatic cancer mutation
NCT ID NCT07644559
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests a new oral drug, VS-7375, alone or with another drug (cetuximab), in 180 people with metastatic pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug shrinks tumors and is safe. Participants must have this mutation and be in relatively good health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VS-7375 (a pill that targets a specific cancer mutation) and cetuximab (an infusion drug)
What this could lead to
If successful, this could provide a new treatment option for people with a hard-to-treat form of pancreatic cancer that has a specific genetic mutation.
What could go wrong
This is a phase 2 trial, so it's still early. The drug may not work better than current treatments, and side effects could be significant. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ICON Cancer Centre
RECRUITINGSouth Brisbane, QLD 4101, Australia
Contact Email: •••••@•••••
Contact
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Email: •••••@•••••
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77054, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact Email: •••••@•••••
Contact
-
START Dallas
RECRUITINGFort Worth, Texas, 76104, United States
Contact Email: •••••@•••••
Contact
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact Email: •••••@•••••
Contact
-
START New Jersey
RECRUITINGEast Brunswick, New Jersey, 08816, United States
Contact
Contact Email: •••••@•••••
-
START- Los Angeles
RECRUITINGLos Angeles, California, 90025, United States
Contact Email: •••••@•••••
Contact
-
START- Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
Contact Email: •••••@•••••
Contact
-
START- San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Contact Email: •••••@•••••
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UVA Health
RECRUITINGCharlottesville, Virginia, 22903, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Email: •••••@•••••